{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:43:53Z","timestamp":1740116633228,"version":"3.37.3"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010618","name":"Guangzhou University of Chinese Medicine","doi-asserted-by":"crossref","award":["018A1AFD018171Z11073"],"award-info":[{"award-number":["018A1AFD018171Z11073"]}],"id":[{"id":"10.13039\/501100010618","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010618","name":"Guangzhou University of Chinese Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010618","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clineuro.2018.07.023","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T16:43:46Z","timestamp":1532969026000},"page":"70-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis"],"prefix":"10.1016","volume":"173","author":[{"given":"Li-Na","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Jun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Man","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Long","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang-Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Feng","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2018.07.023_bib0005","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J. Antibiot."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0020","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.4049\/jimmunol.141.10.3361","article-title":"Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis","volume":"141","author":"Fujii","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0896-8411(89)90267-9","article-title":"High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes from patients with myasthenia gravis: correlations with clinical parameters","volume":"2","author":"Cohen-Kaminsky","year":"1989","journal-title":"J. Autoimmun."},{"year":"2008","series-title":"Myasthenia Gravis A Manual for the Health Care Provider","author":"Howard","key":"10.1016\/j.clineuro.2018.07.023_bib0030"},{"key":"10.1016\/j.clineuro.2018.07.023_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20517\/2347-8659.2015.60","article-title":"China guidelines for the diagnosis and treatment of myasthenia gravis","volume":"3","author":"Li","year":"2016","journal-title":"Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0040","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.12659\/MSM.902442","article-title":"Metastatic thymoma-associated myasthenia gravis: favorable response to steroid pulse therapy plus immunosuppressive agent","volume":"23","author":"Qi","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jns.2013.06.018","article-title":"Myasthenia gravis: New therapeutic approaches based on pathophysiology","volume":"333","author":"Lewis","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0060","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0070","first-page":"976","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis [REGAIN]: a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"12","author":"Jr","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refratory myasthenia gravis to rituximab: a retrospective study","volume":"5","author":"Nowak","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clin. Immunol. Imunopathol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0090","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1128\/MCB.11.8.4074","article-title":"The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1","volume":"11","author":"Banerji","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0095","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2007.12.008","article-title":"Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis","volume":"195","author":"Furukawa","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0105","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.clinph.2012.01.017","article-title":"Early effect of tacrolimus in improving excitation-contraction coupling in myasthenia gravis","volume":"123","author":"Imai","year":"2012","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0110","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1016\/S0021-9258(19)49416-7","article-title":"The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum","volume":"268","author":"Timerman","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jocn.2004.12.008","article-title":"Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone","volume":"13","author":"Shimojima","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0120","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Intern. Med."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0125","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2018.07.023_bib0130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK 506 [tacrolimus]","volume":"76","author":"Konishi","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","article-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus [FK506] for myasthenia gravis","volume":"247","author":"Tada","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0145","first-page":"497","article-title":"Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0150","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2018.07.023_bib0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","article-title":"Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis","volume":"300","author":"Minami","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis \u2013 a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2169\/internalmedicine.9167-17","article-title":"Myasthenia gravis complicated with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), following thymectomy and longstanding tacrolimus therapy","volume":"57","author":"Ohara","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2018.07.023_bib0180","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079907X188080","article-title":"Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study","volume":"23","author":"Ponseti","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0185","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatric Neurolog"},{"key":"10.1016\/j.clineuro.2018.07.023_bib0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/aian.AIAN_97_17","article-title":"Efficacy and safety of tacrolimus in myasthenia gravis: a systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2017","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jns.2017.05.060","article-title":"A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis","volume":"79","author":"Ahn","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","article-title":"Benefits of FK506 [tacrolimus] for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study","volume":"107","author":"Ponseti","year":"2005","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0210","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1212\/01.wnl.0000218665.94920.5e","article-title":"Long-term results of tacrolimus in cyclopsorine and prednisone-dependent myasthenia gravis","volume":"66","author":"Sanders","year":"2006","journal-title":"Neurolog"},{"key":"10.1016\/j.clineuro.2018.07.023_bib0215","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0220","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies ingeneralized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2018.07.023_bib0225","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0230","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy lowers the myasthenia gravis biomarker miR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0235","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jneuroim.2015.10.018","article-title":"Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese","volume":"289","author":"Lee","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2018.07.023_bib0240","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384671830310X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384671830310X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T01:45:35Z","timestamp":1693791935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030384671830310X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":48,"alternative-id":["S030384671830310X"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2018.07.023","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2018.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}